Compare · AZN vs TCRT
AZN vs TCRT
Side-by-side comparison of AstraZeneca PLC (AZN) and Alaunos Therapeutics Inc. (TCRT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AZN and TCRT operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- AZN is the larger of the two at $575.85B, about 8273.3x TCRT ($69.6M).
- Over the past year, AZN is down 1.4% and TCRT is up 13.5% - TCRT leads by 14.9 points.
- AZN has been more active in the news (21 items in the past 4 weeks vs 7 for TCRT).
- AZN has more recent analyst coverage (25 ratings vs 1 for TCRT).
- Company
- AstraZeneca PLC
- Alaunos Therapeutics Inc.
- Price
- $185.74+0.19%
- $2.94+20.00%
- Market cap
- $575.85B
- $69.6M
- 1M return
- +0.27%
- +17.60%
- 1Y return
- -1.35%
- +13.51%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2026
- News (4w)
- 21
- 7
- Recent ratings
- 25
- 1
AstraZeneca PLC
AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; Alchemab to enhance prostate cancer research; and Proteros biostructures GmbH to discover and develop novel small molecules for the treatment of various types of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Alaunos Therapeutics Inc.
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers; hunTR, a human neoantigen T-cell receptor platform; and mbIL-15 to treat solid tumors. Alaunos Therapeutics, Inc. has a license agreement with PGEN Therapeutics, Inc.; research and development agreement with The University of Texas MD Anderson Cancer Center; and a patent license agreement, and research and development agreement with the National Cancer Institute. The company was formerly known as ZIOPHARM Oncology, Inc. and changed its name to Alaunos Therapeutics, Inc. in January 2022. Alaunos Therapeutics, Inc. is headquartered in Houston, Texas.
Latest AZN
- SEC Form 6-K filed by AstraZeneca PLC
- IMFINZI® (durvalumab) approved in the US in first and only immunotherapy combination for patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer
- SEC Form 25-NSE filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- Officer Sharma Mani sold $2,209,482 worth of Ordinary Shares (11,893 units at $185.78), decreasing direct ownership by 38% to 19,262 units (SEC Form 4)
- DATROWAY® (datopotamab deruxtecan-dlnk) approved in the US as first TROP2-directed antibody drug conjugate for 1st-line treatment of patients with metastatic triple-negative breast cancer who are not PD-1/PD-L1 inhibitor candidates
- Datroway® Approved in the U.S. as First TROP2 Directed Antibody Drug Conjugate for First-Line Treatment of Patients with Metastatic Triple Negative Breast Cancer Who Are Not PD-1/PD-L1 Inhibitor Candidates
Latest TCRT
- Chief Executive Officer Weis Holger was granted 3,700 shares, increasing direct ownership by 306% to 4,911 units (SEC Form 4)
- Alaunos Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Alaunos Reports Broad Metabolic Improvements with ALN1003 in Obese Mouse Studies
- Alaunos Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Alaunos Reports Preclinical ALN1003 Data Showing Effects on Insulin-Resistance-Related Biomarkers and Liver Histology in Diet-Induced Obesity Models
- SEC Form 10-Q filed by Alaunos Therapeutics Inc.
- Valion Bio Appoints Melinda Lackey as General Counsel
- Director Vieser Jaime was granted 6,515 shares, increasing direct ownership by 20% to 38,853 units (SEC Form 4)
- Director Postma Robert W was granted 6,274 shares, increasing direct ownership by 14% to 50,146 units (SEC Form 4)
- Director Jerman Michael Allen was granted 6,032 shares, increasing direct ownership by 63% to 15,621 units (SEC Form 4)